Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
This study has been completed.
Sponsor:
Novartis
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00171665
First received: September 13, 2005
Last updated: October 9, 2006
Last verified: October 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis |
Drug: Diclofenac topical sodium gel 1% |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- OA pain intensity in target hand at Week 4 and 6
- Total AUSCAN score in target hand at Week 4 and 6
- Global rating of disease activity by patient at Week 4 and 6
Secondary Outcome Measures:
- OA pain intensity and total AUSCAN score in target hand, and global rating of disease activity by patient at Weeks 1, 2 and 8
- AUSCAN pain, stiffness and physical function scores in target hand, and global rating of benefit by patient at Weeks 1, 2, 4, 6 and 8
- OA pain intensity in target hand and use of rescue medication recorded in diary
- Global evaluation of treatment at final visit
- Treatment responder rate according to OARSI criteria
| Estimated Enrollment: | 360 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | December 2005 |
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion criteria:
• Osteoarthritis of the hand
Key Exclusion Criteria:
- Other rheumatic disease, such as rheumatoid arthritis
- Active gastrointestinal ulcer during the last year
- Known allergy to analgesic drugs
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00171665
Show 70 Study Locations
Show 70 Study LocationsSponsors and Collaborators
Novartis
More Information
No publications provided by Novartis
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00171665 History of Changes |
| Other Study ID Numbers: | VOSG-PE-315 |
| Study First Received: | September 13, 2005 |
| Last Updated: | October 9, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Novartis:
|
Hand osteoarthritis, Topical NSAID, Diclofenac sodium |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Diclofenac Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013